Salt Lake City-based ProLung filed an initial public offering with the goal of raising up to $8 million. The company is developing a test for early risk stratification for lung cancer.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.